Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Stock Regains Lost Ground From Tumble Following Last Week s Q3 Report

NEW YORK, Nov. 3 (GenomeWeb News) - Shares in Harvard Bioscience closed up 6.56 percent on Wednesday, regaining ground lost since the company released lackluster revenue growth on Oct. 29.

 

The firm's shares closed up at $4.20 on the Nasdaq exchange, eclipsing the closing price for its shares just before it released its Q3 results on Oct. 29. The third-quarter earning sreport caused the company's shares to tumble 

more that 9 percent to close $3.70 on Oct. 29 from $4 the day before.

 

Last week, Harvard said its poorly performing Genomic Solutions unit acted as ballast on third-quarter revenue. The firm posted Q3 revenue of $23.2 million, up from $21.1 million in the comparable period a year ago. Harvard also lowered by $2.2 million its revenue outlook for the fourth quarter.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.